An interventional study of electroacupuncture and lifestyle modification in Polycystic Ovarian Syndrome and Obesity, Abdominal, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 2 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-09-12.
Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 55th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2016, is one of 51 with no phase, and was the 23rd registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40 · Women only
Shanghai First Maternity and Infant Hospital · Sites in China
Ages 19–40 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 7 · Phase 4 14
First in 2008; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 100 across the 86 interventional studies, 300 across the 21 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 107 have an industry lead sponsor. The 10 most frequent:
Dongfang Hospital Beijing University of Chinese Medicine is the lead sponsor of 10 studies on the registry; none are open to participants now.
Dongfang Hospital Beijing University of Chinese Medicine has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739940Guangdong Women and Children HospitalClinical Research Cohort for Polycystic Ovary Syndrome | 2026-12-01 |
| NCT07739953Guangdong Women and Children HospitalDevelopment and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome | 2026-12-31 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT07616037Shanghai Zhongshan HospitalEfficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the use of electroacupuncture to dredge and regulate Dai Meridian combined with lifestyle modification are more effective than lifestyle modification only in the treatment of anovulation and hyperandrogenism due to polycystic ovary syndrome (PCOS) with abdominal obesity.Two thirds of participants will receive electroacupuncture and lifestyle modification in combination, while the other one third will receive lifestyle modification only.
Obesity, especially abdominal obesity, is one of most common clinical features of polycystic ovary syndrome, a widely and seriously influenced complex disorder related to reproduction and metabolism. Excessive accumulation of adipose tissue in the abdominal organs often leads to insulin resistance, which will increase the harm of hyperandrogenism and exacerbate ovulation disorders and metabolic abnormalities.
Weight loss, likely beneficial for both reproductive and metabolic dysfunction in this setting , has been generally recommended as a first-line therapy for obese women with PCOS and can be accomplished via lifestyle modification and electroacupuncture. What's more, stimulating acupoints of Dai Meridian can regulate menstrual cycles and treat infertility according to the theory of traditional Chinese medicine. However, how much benefits patients will additionally get from the Combined therapy is not clear now.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
Device: electroacupuncture · Behavioral: lifestyle modification
diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
Behavioral: lifestyle modification
Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
rate of recovered ovulation
the proportion of patients who have ovulation after treatment
Time frame: 12 weeks
evidence of clinically definite hyperandrogenism confirmed by mF-G score
Time frame: 12 weeks
evidence of clinically definite hyperandrogenism confirmed by the Global Acne Grading System
Time frame: 12 weeks
frequency of menstruation
Time frame: 12 weeks
quantity of menstruation
pictorial blood loss assessment chart
Time frame: 12 weeks
Serum total testosterone (T)
Time frame: 12 weeks
FSH
follicle stimulating hormone (FSH)
Time frame: 12 weeks
LH
luteinizing hormone (LH)
Time frame: 12 weeks
ovarian volume measured by ultrasound
Time frame: 12 weeks
follicle number pre ovary measured by ultrasound
Time frame: 12 weeks
ovarian stromal blood flow measured by ultrasound
Time frame: 12 weeks
body weight in kilograms
Time frame: 4, 8 and 12 weeks
waist circumference in centimeter
Time frame: 4, 8 and 12 weeks
BMI in kg/m^2
Time frame: 4, 8 and 12 weeks
waist-to-height ratio
waist-to-height ratio=waist circumference in centimeter/height in centimeter
Time frame: 4, 8 and 12 weeks
Fasting serum PAI-1 level
Time frame: 12 weeks
International physical activity scale (IPAQ) short version
Time frame: 4, 8 and 12 weeks
Plan to share: Undecided
The record gives a start of Jul 2016, a primary completion of Jan 2019 and a completion of Sep 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongfang Hospital Beijing University of Chinese Medicine